Allergan (NYSE:AGN) and its nonprofit partner, Medicines360, touted five-year data today from an on-going pivotal trial of its intrauterine device, Liletta.
The levonorgestrel-releasing contraceptive is approved in the U.S. to be used to prevent pregnancy for up to four years.
Get the full story at our sister site, Drug Delivery Business News.
The post Allergan touts 5-year data for Liletta intrauterine contraceptive appeared first on MassDevice.